Governance Damora Therapeutics, Inc.

DMRA

KYG2646Y1044

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 14:53:29 22/07/2026 BST			5-day change	1st Jan Change
31.72 ^USD	-3.85%		+5.22%	+41.53%

07-17	Damora Therapeutics Completes Redomestication to Cayman Islands	MT
06-29	Damora Therapeutics, Inc.(NasdaqCM:DMRA) added to Russell Small Cap Comp Growth Benchmark	CI

Executive Committee: Damora Therapeutics, Inc.

Manager

Positions heldSince

Jennifer Jarrett

55 year

Chief Executive Officer	29/03/2026
President	29/03/2026

Garrett Winslow

47 year

General Counsel	10/05/2021
Corporate Secretary	10/05/2021

Becker Hewes

60 year

Chief Tech/Sci/R&D Officer

04/01/2026

Brian Burkavage

Comptroller/Controller/Auditor	30/04/2026
Director of Finance/CFO	30/04/2026

Jim Baker

Investor Relations Contact	30/04/2026
Public Communications Contact	30/04/2026

Composition of the Board of Directors: Damora Therapeutics, Inc.

Director

CommitteesSince

Peter Harwin

40 year

Governance Committee
Nominating Committee
Compensation Committee	28/08/2024
Governance Committee Chair	22/03/2026
Nominating Committee Chair	22/03/2026

Christopher Cain

42 year

Compensation Committee	27/04/2025
Governance Committee Chair	09/03/2025
Nominating Committee Chair	09/03/2025
Governance Committee	09/11/2025
Nominating Committee	09/11/2025
Compensation Committee Chair	09/11/2025

Jennifer Jarrett

55 year

Governance Committee	21/04/2025
Nominating Committee	21/04/2025
Audit Committee	31/07/2024
Compensation Committee	21/04/2025

Michael Landsittel

54 year

Governance Committee	22/03/2026
Nominating Committee	22/03/2026
Audit Committee Chair	22/03/2026

Julianne Bruno

41 year

Audit Committee	09/11/2025
Compensation Committee	09/11/2025

Cameron Turtle

36 year

Audit Committee

22/03/2026

Latest Appointments: Damora Therapeutics, Inc.

05-04	Damora Therapeutics, Inc. Announces Departure of Lori Firmani as Chief Financial Officer, Effective May 1, 2026	CI
05-04	Damora Therapeutics, Inc. Announces Appointment of Brian Burkavage as Principal Financial Officer and Principal Accounting Officer, Effective May 1, 2026	CI
03-23	Damora Therapeutics, Inc. Announces Chief Executive Officer Changes, Effective March 30, 2026	CI
03-23	Damora Therapeutics, Inc. Announces Executive and Board Changes	CI
02-10	Galecto Inc Hans T. Schambye to Cease Serving as CEO and President	RE
02-10	Galecto, Inc. Announces Management Changes, Effective from February 10, 2026	CI
02-10	Galecto, Inc. Announces CEO Changes, Effective February 10, 2026	CI

More news

Former Officers and Directors: Damora Therapeutics, Inc.

Insider

Positions held

SinceUntil

Lori Firmani

Comptroller/Controller/Auditor	31/07/2024	30/04/2026
Director of Finance/CFO	31/07/2024	30/04/2026

Sherwin Sattarzadeh

Chief Executive Officer	09/02/2026	29/03/2026
Chief Operating Officer	04/01/2026	29/03/2026

Carl Goldfischer

Director/Board Member	31/12/2019	-
Chairman	30/06/2021	22/03/2026
Independent Dir/Board Member	31/12/2019	22/03/2026

Jayson Dallas

Director/Board Member	18/11/2020	22/03/2026
Independent Dir/Board Member	18/11/2020	22/03/2026

Amit Munshi

Director/Board Member	-	22/03/2026
Chairman	18/05/2020	-
Independent Dir/Board Member	-	22/03/2026

Hans Schambye

Director/Board Member	31/12/2019	09/02/2026
Chief Executive Officer	31/10/2011	09/02/2026
Chief Tech/Sci/R&D Officer	30/09/2023	04/01/2026
Founder	31/12/2010	09/02/2026
President	31/12/2010	09/02/2026

Anders Pedersen

Chief Operating Officer

31/12/2019

04/01/2026

David Shapiro

Director/Board Member	18/05/2020	09/11/2025
Independent Dir/Board Member	18/05/2020	09/11/2025

Amy Wechsler

Director/Board Member	10/10/2024	09/11/2025
Independent Dir/Board Member	10/10/2024	09/11/2025

Anne Prener

Director/Board Member	07/01/2021	09/11/2025
Independent Dir/Board Member	07/01/2021	09/11/2025

Stephanie Oestreich

Corporate Officer/Principal

04/01/2022

30/09/2024

Matthew Kronmiller

Corporate Officer/Principal

30/09/2024

Jonathan Freve

Director of Finance/CFO

31/03/2020

31/07/2024

Søren Møller

Director/Board Member	31/12/2019	19/06/2024
Independent Dir/Board Member	31/12/2019	19/06/2024

Chau Khuong

Director/Board Member	31/12/2017	19/06/2024
Independent Dir/Board Member	31/12/2017	19/06/2024

Bertil Lindmark

Chief Tech/Sci/R&D Officer

31/01/2020

30/09/2023

Stephan Christgau

Director/Board Member

31/08/2020

25/05/2021

Gunnar Magnus Modee Persson

Chairman

18/05/2020

Jakob Dynnes Hansen

Corporate Secretary

31/03/2020

Erez Chimovits

Director/Board Member

31/12/2019

Chandra Paul Leo

Director/Board Member

31/12/2019

Karen Wagner

Director/Board Member

31/12/2019

Søren Lemonius

Director/Board Member

31/12/2019

Hakon Leffler

Founder

31/12/2010

Ulf Jörgen Nilsson

Founder

31/12/2010

Tariq Sethi

Founder

31/12/2010

Steven Spector

General Counsel

Rob Slack

Chief Tech/Sci/R&D Officer

Age distribution of managers

Parity Men Women

Male	8
Female	2

Of which Executive Committee

Male	4
Female	1

Of which Directors

Male	4
Female	2

Damora Therapeutics Inc, formerly Galecto, Inc, is a clinical-stage biotechnology company focused on the development of novel treatments for cancer and liver diseases. The Company is engaged in the advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is significant medical need for disease-modifying treatments. It offers a multiple programs including asset, DMR-001, an investigational monoclonal antibody therapy targeting mutCALR. DMR-001 was designed to exclusively bind to mutCALR with exquisite selectivity, potency, and extended half-life, with potential to enable convenient, infrequent subcutaneous dosing.

Employees

Sector

Biotechnology & Medical Research

More about the company